TABLE 3.
Self-reported clinical obesity services offered by American Board of Obesity Medicine (ABOM) Diplomates
| ABOM Diplomates (n = 494) | Treats majority adults (n = 450) | Treats majority children (n = 43) | P-valuea | |
|---|---|---|---|---|
| Clinical services | ||||
| Nutrition | 90.1% | 90.4% | 86.1% | .36 |
| Meal replacements | 47.0% | 49.3% | 23.3% | <.01 |
| Physical activity | 67.8% | 66.9% | 76.7% | .19 |
| Behavioural services | 66.2% | 66.0% | 69.8% | .62 |
| Mental health services | 76.7% | 76.7% | 79.1% | .72 |
| Minimally invasive bariatric procedures/devices | 24.3% | 26.2% | 4.7% | <.01 |
| Perioperative bariatric surgical care | 63.0% | 65.1% | 39.5% | <.01 |
| Medications and supplements | ||||
| FDA-approved anti-obesity medications | <.01 | |||
| Prescribes | 83.4% | 86.2% | 53.5% | |
| Does not prescribe | 7.5% | 4.7% | 37.2% | |
| Not disclosed | 9.1% | 9.1% | 9.3% | |
| Types of FDA-approved medications used | <.01 | |||
| Short-term medications only | 5.5% | 4.9% | 11.6% | |
| Short- and long-term medications | 70.9% | 75.3% | 23.3% | |
| Long-term medications only | 7.1% | 6.0% | 18.6% | |
| None/Not disclosed | 16.6% | 13.8% | 46.5% | |
| Off-label medications for weight loss | .02 | |||
| Prescribes | 76.9% | 78.0% | 67.4% | |
| Does not prescribe | 14.2% | 12.7% | 27.9% | |
| Not disclosed | 8.9% | 9.3% | 4.7% | |
| Supplements/other products used | <.01 | |||
| No | 66.2% | 64.0% | 88.4% | |
| Yes | 25.1% | 26.9% | 7.0% | |
| Not disclosed | 8.7% | 9.1% | 4.7% |
Abbreviations: ABOM, American Board of Obesity Medicine; FDA, Food and Drug Administration.
a
P-values calculated using Chi square tests comparing Diplomates who reported treating a majority adults as compared to those treating a majority children/adolescents.